EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes

Allison Mo iD, Erica Wood, Jake Shortt, Andrew Charlton, Dorothea Evers, Marlijn Hoeks, Elizabeth Pritchard, James Daly, Carol Hodgson, Stephen Opat, David Bowen, John Reynolds und 3 weitere

Transfusion · 2024

DOI: 10.1111/trf.17706 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Transfusion, 2024. Verfasst von Allison Mo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Australia. Hauptthemen laut MEDLINE: Anemia, Myelodysplastic Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Newcastle Hospitals Charitable Funds, Charity at Leeds, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anemia in myelodysplastic syndromes (MDS) is associated with poorer health‐related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2–4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low‐dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes. Study Design and Methods In this n‐of‐1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended‐matched RBCs are provided, with transfusion based upon the previous week's Hb/pre‐transfusion testing results to eliminate delays of awaiting contemporaneous cross‐matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences.

Results

The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter‐country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units.

Discussion

This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre‐transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaMyelodysplastic SyndromesHumansFeasibility StudiesPilot ProjectsQuality of LifeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

RBC transfusiontransfusion practices (adult)transfusion practices (oncology-hematology)

Autor:innen und Institutionen

  • Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Australia.
  • Department of Haematology, Monash Health, Clayton, Australia.
  • Austin Pathology & Department of Haematology, Austin Health, Heidelberg, Australia.
  • Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
  • Department of Haematology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
  • Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.

ORCID-Profile: Allison Mo, Le Thi Phung Thao, Zoe McQuilten

Förderung

  • Newcastle Hospitals Charitable Funds
  • Charity at Leeds
  • National Health and Medical Research Council
  • National Blood Authority
  • Monash Haematology
  • Australian and New Zealand Society of Blood Transfusion

Zitieren

APA

Mo, A., Wood, E., Shortt, J., Charlton, A., Evers, D., Hoeks, M., Pritchard, E., Daly, J., Hodgson, C., Opat, S., Bowen, D., Reynolds, J., Thi Phung Thao, L., Stanworth, S. J., & McQuilten, Z. (2024). Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes. Transfusion. https://doi.org/10.1111/trf.17706

Vancouver

Mo A, Wood E, Shortt J, Charlton A, Evers D, Hoeks M, et al. Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes. Transfusion. 2024. doi:10.1111/trf.17706

BibTeX
@article{Mo2024,
  author = {Mo, Allison and Wood, Erica and Shortt, Jake and Charlton, Andrew and Evers, Dorothea and Hoeks, Marlijn and Pritchard, Elizabeth and Daly, James and Hodgson, Carol and Opat, Stephen and Bowen, David and Reynolds, John and Thi Phung Thao, Le and Stanworth, Simon J and McQuilten, Zoe},
  title = {Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17706}
}
Kostenlos starten →